Please login to the form below

Not currently logged in
Email:
Password:

EGFR mutation

This page shows the latest EGFR mutation news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Tagrisso's first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS

AstraZeneca sees lots of room for growth, especially China and other Asian markets where there are a high proportion (30-40% of Asian NSCLC patients who the EGFR mutation at diagnosis. ... The progression-free survival benefit seen in the trial is

Latest news

  • Clock starts ticking on AZ’s first-line lung cancer filing in US Clock starts ticking on AZ’s first-line lung cancer filing in US

    Third-generation EGFR inhibitor Tagrisso (osimertinib) is already approved as a follow-up to older drugs in the class, including AZ’s own Iressa (gefitinib) product and Roche's Tarceva (erlotinib), ... were updated to include the use of Tagrisso in the

  • AZ pushes harder into China with new joint venture AZ pushes harder into China with new joint venture

    The company made China a priority market for the roll-out of new lung cancer therapy Tagrisso (osimertinib), claiming approval for the EGFR inhibitor from the China Food and Drug Administration ... Asian patients with NSCLC have the EGFR mutation at

  • AZ starts pursuit of lung cancer indication for Imfinzi AZ starts pursuit of lung cancer indication for Imfinzi

    AZ starts pursuit of lung cancer indication for Imfinzi. And its EGFR inhibitor Tagrisso picks up US breakthrough status. ... The FDA awarded the status to the next-generation EGFR inhibitor for the first line treatment of patients with metastatic EGFR

  • AZ buoyed by latest lung cancer data at ESMO AZ buoyed by latest lung cancer data at ESMO

    to just over 10 months for first-generation EGFR-targeting drugs, Roche's Tarceva (erlotinib) and AZ's own Iressa (gefitinib). ... Until now, even with the therapeutic advances offered by the first- and second-generation EGFR inhibitors, less than 20% of

  • AZ gets rapid approval in China for Tagrisso AZ gets rapid approval in China for Tagrisso

    with NSCLC have the EGFR mutation at diagnosis. ... This is an important step forward for Tagrisso and a significant opportunity to bring a breakthrough medicine to patients with NSCLC in China, where EGFR mutation rates are some of the

More from news
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • Harnessing complexity Harnessing complexity

    While more established methodologies still dominate, Next Generation Sequencing is starting to make an impact in the Oncology CDx world, as this breakdown of methodologies used for EGFR mutation testing in

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation ... in the EGFR-TK gene and Lynparza, which is

  • Diagnostics are rising up the pharma value chain Diagnostics are rising up the pharma value chain

    lung cancer, which was backed together with Roche Diagnostics' cobas EGFR Mutation Test. ... He adds: “ What do we do when a person says they have a mutation of this type of cancer and there seems to be a drug.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. “ ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    which received the green light as a treatment for patients with non-small cell lung cancer (NSCLC) who have the epidermal growth factor receptor (EGFR) gene mutation.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics